Clinical Trials
46 trialsCAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Eli Lilly and Company
innovaTV 301
Seagen Inc.
CheckMate 816
Bristol-Myers Squibb
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
IPSOS
Hoffmann-La Roche
TROPiCS-02
Gilead Sciences
RIGHT Choice
Novartis
ARCTIC
AstraZeneca
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
Pierre Fabre Medicament
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
TULIP
Byondis B.V.
ATTAIN
Nektar Therapeutics
ASCENT
Gilead Sciences
KEYNOTE-119
Merck Sharp & Dohme LLC
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Bayer
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
CTI BioPharma
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Boehringer Ingelheim
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
Boehringer Ingelheim
StepUp
Pierre Fabre Pharma GmbH
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Eisai Inc.
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Puma Biotechnology, Inc.
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
Puma Biotechnology, Inc.
VITAL
Novartis
BOLERO-3
Novartis
INV181
Novartis
CERTO
Merck KGaA, Darmstadt, Germany
VELVET
Hoffmann-La Roche
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
Hoffmann-La Roche
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
Pierre Fabre Medicament
CARIN
iOMEDICO AG
Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC
Sanofi
PROCLAIM
Eli Lilly and Company
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
Eli Lilly and Company
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Boehringer Ingelheim
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Hoffmann-La Roche
FLEX
Merck KGaA, Darmstadt, Germany
Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy
Pierre Fabre Medicament
Lapatinib in Combination With Vinorelbine
GlaxoSmithKline
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
Mast Therapeutics, Inc.
Study of CipterbinĀ®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer
Shanghai CP Guojian Pharmaceutical Co., Ltd.
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
Eli Lilly and Company
GON
Sanofi
Phase II Iressa Versus Vinorelbine (INVITE)
AstraZeneca
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
AstraZeneca
A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer
Eli Lilly and Company